
GI oncologist and researcher @UCIAntiCancer. Tweets are my own opinions. RTs are not commercial endorsements.
Joined September 2017
- Tweets846
- Following281
- Followers630
- Likes942
Pinned Tweet
Three journeys of young onset colorectal cancers! “Dr. Cho told me to let her worry about the cancer and for me to worry about starting my brewery,” he recalled. Trinity County Brewing Company @TrinityBrewery opened in May 2020! health.ucdavis.edu/synthesis… @sepideh_gholami @HalabiMd
May Cho retweeted
ctDNA-based MRD & survival in resectable CRC
@NatureMedicine
doi.org/10.1038/s41591-024-0…
🔎CIRCULATE-🇯🇵 GALAXY, 2,240 pts
👉shorter DFS in MRD+ patients
👉Better outcome after sustained ctDNA clearance in response to ACT
🧐What else do we need to implement into clinical practice?
@myESMO
May Cho retweeted
Clinical Outcomes of Elective Early Discontinuation of Immunotherapy Based on Objective Response in Microsatellite … pubmed.ncbi.nlm.nih.gov/3925…
Our single center experience as summarized by our super Fellow Dr. Annie Xioa supports early discontinuation in settings of Clinical CR.
May Cho retweeted
I will be riding in my 6th closer to free bike ride on 9/7/2024. The ride is a great experience to join the Yale Cancer Center community and support cancer research. Please support my ride at the following link:
rideclosertofree.org/partici…
My goal is to raise at least $500!
May Cho retweeted
From @asco as led by: @ajscott40 @sepidah_gholami @MyriamChalabi @HKennecke @MayCho_MD @manjuggm @JoshSmithMDPhD : Management of Locally Advanced Rectal Cancer: ASCO Guideline pubmed.ncbi.nlm.nih.gov/3911… #crcsm #rectalcancer #cancer #CancerResearch @OncoAlert
Who would not love working with @HKennecke!!!
Replying to @HKennecke @ASCO @ajscott40 @VanMorrisMD @manjuggm @jonathanloree @JoshSmithMDPhD @jordanberlin5 @MayCho_MD @lisakachnic1
Loved working with you on this! Your insights are always so valuable.
3
159
Universe listens to your inner voice. Been wanting to meet this inspiring @realbowtiedoc and got a chance to have “peer mentoring” session and learned how he’s improving much needed pall care for GI Onc pts since the first day of their journeys!
A favorite #SuppOncSelfies📸 with luminary @MayCho_MD at @ASCOTECAG lounge. These 1-on-1 mentoring sessions are so cherished. Her wisdom "That queasy feeling you get is moving from a comfort to a growth mindset" So honored to have time at the table with her #ASCO24 #GIonc
14
505
May Cho retweeted
💊Adding durvalumab plus bevacizumab to TACE in unresectable HCC
EMERALD-1, @ASCO GI24
@JCO_ASCO
✅D+B+TACE vs TACE
mPFS: 15.0 vs 8.2 mo, HR: 0.77 (0.61–0.98) p=0.032
❌D+TACE vs TACE
mPFS: 10.0 vs 8.2 mo, HR: 0.94 (0.75–1.19) p=0.638
👉ascopubs.org/doi/10.1200/JCO…
⁉️Whether it may change the practice may depend on OS. Patients continue to be followed for OS
@JCOPO_ASCO @liver_cancer @BCLC_group @TimGreten @kmody29 @Amitmahipal79 @AndrewMMoon
#cancer #oncology #liver #hcc #MedX
Only @jgong15 can do this! Has been writing/publishing dual/triple since fellowship @COHMedOnc with @mgfakih and @montypal!
Congrats @Cecchini_OncMD! You have incubated this project since fellowship!
A new study from @Cecchini_OncMD and colleagues at Yale Cancer Center found olaparib and ramucirumab is well-tolerated with efficacy for metastatic #gastriccancer and #GEJadenocarcinoma. @SmilowCancer @YaleMed @YNHH
nature.com/articles/s41416-0…
1
5
531
May Cho retweeted
A new study from @Cecchini_OncMD and colleagues at Yale Cancer Center found olaparib and ramucirumab is well-tolerated with efficacy for metastatic #gastriccancer and #GEJadenocarcinoma. @SmilowCancer @YaleMed @YNHH
nature.com/articles/s41416-0…
May Cho retweeted
In MSI high mCRC Ipi Nivo was dramatically superior to chemo first line with marked improved PFS. Results of Nivo alone awaited. Establishes a new first line option in MSI high mCRC.
May Cho retweeted
Liver Metastases & Immune Checkpoint Inhibitor Efficacy in Refractory mCRC
@JAMANetworkOpen
doi.org/10.1001/jamanetworko…
🔎CCTG CO.26 trial
👉Pts without LM have significantly improved
DCR, PFS & OS with Durva/Treme vs BSC
🧐consistent finding, important for future trial design
@myESMO
May Cho retweeted
Yet another clinical trial failure by applying “targeted” therapy in an un-targeted fashion. While some cancer type have germ-line mutations (e.g., BRCA) which allow broader use of this drug class, NSCLC is not one of them. Even when BRCA-mutated, in NSCLC most are mono-allelic – at California, USA
Press release: Phase III KEYLYNK-008 closes for futility. Addition of maintenance olaparib (PARP inhibitor) after first-line pembrolizumab + chemotherapy in squamous NSCLC did not improve PFS or OS. Numerically longer PFS, not significant. Await details.
businesswire.com/news/home/2…
I couldn’t be more proud of my fav partner-in-crime, amazing clinician and scientist, the best writer and human being…@jgong15. Nature for 5 yrs in and NEJM next! nature.com/articles/s41585-0…
May Cho retweeted
We use a novel 2-mo RECIST organ-specific response assessment to dissect the impact of IO on responses in different sites of MSS MCRC. Check the article to learn more on how sites of metastases impact response. Liver, lung, peritoneum, and others- ejcancer.com/article/S0959-8…
Congrats @jtmoyers!!!🎉🎊 This is such an accomplishment within 6 months of arrival @AnglesClinic!!!
Molecular Templates First Patient Dosed Phase 1 Trial MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors - proud to have dosed the first patient and moved the story of anti-CTLA4 forward @angelesclinic @jtmoyers
mtem.com/investors/news-even…
1
2
351
May Cho retweeted
🎯Raludotatug deruxtecan R-DXd (CDH6 #AntibodyDrugCongugate) yields objective response rate of 46% and disease control rate of 98% in platinum resistant #OvarianCancer despite a median prior therapies of 4!! #ESMO2023 #gyncsm
May Cho retweeted
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C | NEJM nejm.org/doi/full/10.1056/NE…
Presidential ESMO session today by Dr. Pietrantonio! CodeBreaK 300 Phase 3 trial provides Level One Evidence for Soto + Pmab in KRAS G12C in refractory MCRC.
May Cho retweeted
We think these recommendations will generate ideas for the next generation of #RectalCancer clinical trials. I appreciate leading this work with @PrajnanDasMD, @NCICTEP_ClinRes @CathyEngMD @KarynAGoodman ! – at Saint-Yrieix-le-Déjalat, France
Now out in @JNCI_Now! The consensus recommendations of the NCI Rectal-Anal Task Force members on the design of future clinical trials in rectal cancer. #crsm #rectalcancer @Hkennecke @CathyEngMD Read more here: doi.org/10.1093/jnci/djad143
“As a woman and a female scientist, I told my fellows; you can have both (a family and a career). You don’t need to over-assist your child. Your child will watch you and and they will do!”
“Ten years ago I was kicked out and forced to retire.”
Our new medicine laureate Katalin Karikó (@kkariko) told us how much it means to be awarded the Nobel Prize after a scientific career that has been full of challenges.
Ten years ago, Karikó was still doing all her experiments by hand but today she has been awarded the medicine prize for her research on mRNA, which led to the development of COVID-19 vaccines.
Listen now:
6
463





























